Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12995350 | 0.97 | SGK1 (0.36) | SGK1MAP2K4TBK1JAK2CHEK1 | |
| SCHEMBL12995299 | 0.96 | HRH3 (0.35) | SGK1HRH3MAP2K4TBK1JAK2 | |
| SCHEMBL12995504 | 0.93 | HRH3 (0.35) | SGK1HRH3MAP2K4TBK1JAK2 | |
| SCHEMBL12995346 | 0.93 | SGK1 (0.35) | SGK1HRH3MAP2K4TBK1JAK2 | |
| SCHEMBL12995342 | 0.92 | SGK1 (0.34) | SGK1MAP2K4CYP11B2UCHL1USP30 | |
| SCHEMBL12995926 | 0.90 | SGK1 (0.35) | SGK1MAP2K4UCHL1USP30 | |
| SCHEMBL12995735 | 0.90 | BRD4 (0.39) | SGK1HRH3TBK1JAK2CYP11B2 | |
| SCHEMBL12996261 | 0.90 | HRH3 (0.36) | SGK1HRH3MAP2K4TBK1JAK2 | |
| SCHEMBL12995830 | 0.90 | TBK1 (0.34) | SGK1HRH3TBK1JAK2CHEK1 | |
| SCHEMBL12995925 | 0.90 | SGK1 (0.36) | SGK1MAP2K4UCHL1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | SGK1 2038/4885HRH3 3336/4885MAP2K4 4847/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | SGK1 2038/4885HRH3 3336/4885MAP2K4 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.